DCprime is a clinical-stage cancer immunotherapy company shaping the field of relapse vaccines. At DCprime, we are committed to develop therapeutic vaccines to delay or prevent cancer recurrence. Our lead program, DCP-001, has delivered promising progression-free and overall survival results in advanced-stage Acute Myeloid Myeloma and has shown a safe profile in a Phase I clinical study, providing the basis for an ongoing Phase II clinical study.

We are convinced that there is still a lot to be gained in the treatment of cancer, not only in terms of survival, but also in the quality of life of people living with cancer. DCprime won’t stop to push the boundaries in the cancer vaccine space. We will not only continue to innovate the cancer field by developing relapse vaccines in solid tumors, but also further explore entirely novel vaccination concepts to offer new treatment solutions for patients.

We invest in a broad cancer immunology research network of partners and assembled a highly qualified and experienced team to make the promise of relapse vaccination a reality.

Our Management

Erik Manting, PhD
Chief Executive Officer

Jeroen Rovers, MD PhD
Chief Medical Officer

Our Supervisory Board

Dharminder Chahal
chairman of the Supervisory Board

Andrea van Elsas, PHD
Supervisory Board member

Hans Preusting, PHD MBA
Supervisory Board Member

Our Scientific Advisory Board

Em Prof Dr Ada M. Kruisbeek
Chair of the Scientific Advisory Board

Prof Dr Tanja D. de Gruijl
Scientific Advisory Board Member

Prof Dr Sjoerd H. van der Burg
Scientific Advisory Board Member

Our Investors

Van Herk Groep is the collective name for the businesses and companies belonging to the Van Herk family of Rotterdam. Van Herk Groep was founded by Aat van Herk (1951). Van Herk Ventures invests in the life sciences sector through direct investments in private and listed companies and in venture capital funds. For listed companies, Van Herk invests globally while focusing on the Benelux countries for private companies and venture capital funds.